Pharmacogenomics (PGx)

EP-010 - HYPOXIA INDUCIBLE FACTOR-1A POLYMORPHISMS ASSOCIATED WITH ADVANCED CHRONIC KIDNEY DISEASE.

PT-009 - ASSOCIATION BETWEEN TACROLIMUS AND CYP3A5 GENOTYPE IN PEDIATRIC KIDNEY TRANSPLANT.

PT-020 - FUNCTIONAL CHARACTERIZATION OF ELAVL2 REVEALED THE ROLE OF POST-TRANSCRIPTIONAL REGULATION IN PSYCHIATRIC DISORDERS AND ANTIDEPRESSANT TREATMENT RESPONSE.

PT-025 - A NOVEL REGULATORY VARIANT PROMOTES CYP2D6 ALTERNATIVE SPLICING AND REDUCES FULL-LENGTH CYP2D6 PROTEIN LEVELS IN LIVER SAMPLES.

PT-026 - TRANSCRIPTOMIC PROFILING OF PTRPD KNOCK-DOWN IN HUMAN IPSC-DERIVED NEURONS REVEALED A ROLE IN ALCOHOL USE DISORDER DRUG TREATMENT RESPONSE.

PT-029 - BUILDING A TELEHEALTH PHARMACOGENETIC TESTING PROGRAM IN RURAL AND PEDIATRIC PSYCHIATRY.

EP-011 - METABOLIC PROFILE INVESTIGATION REVEALS WIDE VARIABILITY IN THE EXPOSURE OF ISONIAZID AND ITS HEPATOTOXIC METABOLITES IN TUBERCULOSIS PATIENTS.

PI-022 - ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL.

PI-024 - CHRONIC NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) USE INCREASES GASTRIC TOXICITY: A PHARMACOGENOMIC ANALYSIS.

PI-025 - DOCUMENTATION OF RESULTS AND MEDICATION PRESCRIBING AFTER COMBINATORIAL PSYCHIATRIC PHARMACOGENETIC TESTING.

PI-027 - EFFECT OF GENETIC VARIANTS IN TSPYL ON THE PHARMACOKINETICS OF CYCLOSPORINE.

PI-028 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.

PI-029 - EVALUATION OF THE G6PD VARIANT C.376A>G ACTIVITY IN ALL OF US.

PI-030 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.

PI-032 - THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.

PII-047 - INFLAMMATION DRIVEN INHIBITION OF CYP2C19 METABOLISM OF VORICONAZOLE IN THE TREATMENT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.

PII-049 - MIRNA-125A ASSOCIATION WITH CARFILZOMIB-RELATED CARDIOVASCULAR ADVERSE EVENTS IN MULTIPLE MYELOMA PATIENTS: PROSPECTIVE OBSERVATION OF CARDIAC SAFETY WITH PROTEASOME INHIBITOR (PROTECT) STUDY.

PII-050 - PHARMACOGENOMIC-AUGMENTED DRUG THERAPY IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW OF GENES AND A CASE FOR ARTIFICIAL INTELLIGENCE-AIDED GENOME-WIDE PANEL DESIGN.

PII-051 - PHARMACOGENOMICS OF ACAMPROSATE AND NALTREXONE THERAPY RESPONSE IN ALCOHOL USE DISORDER (AUD)

PII-052 - PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY.

PWIV-005 - THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.

PWIII-002 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.

PWIII-005 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.